Oppenheimer Maintains Outperform on Zimmer Biomet Holdings, Raises Price Target to $155
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Steven Lichtman maintains an Outperform rating on Zimmer Biomet Holdings (ZBH) and raises the price target from $150 to $155.
May 03, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer maintains an Outperform rating on Zimmer Biomet Holdings and raises the price target from $150 to $155.
The increase in price target by a reputable analyst firm like Oppenheimer typically signals a strong confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100